Advice
following a full submission
ustekinumab (Stelara®) is accepted for restricted use within NHS Scotland.
Indication under review: Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug therapy has been inadequate.
SMC restriction: for use in patients with active psoriatic arthritis who have failed on, or are unsuitable for, treatment with an anti-TNF drug.
Significantly more patients with active psoriatic arthritis who were treated with ustekinumab achieved at least 20% response on American College of Rheumatology criteria (ACR 20) at 24 weeks compared with those treated with placebo.
Download detailed advice175KB (PDF)
Medicine details
- Medicine name:
- ustekinumab (Stelara)
- SMC ID:
- 944/14
- Indication:
- Alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying anti-rheumatic drug therapy has been inadequate.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Skin
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 March 2014